154 related articles for article (PubMed ID: 17703109)
1. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function.
Harisi R; Dudas J; Nagy-Olah J; Timar F; Szendroi M; Jeney A
Cancer Biol Ther; 2007 Aug; 6(8):1240-6. PubMed ID: 17703109
[TBL] [Abstract][Full Text] [Related]
2. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix.
Harisi R; Dudás J; Tímár F; Pogány G; Paku S; Tímár J; Kovalszky I; Szendroi M; Jeney A
Anticancer Res; 2005; 25(2A):805-13. PubMed ID: 15868912
[TBL] [Abstract][Full Text] [Related]
3. Repopulation of osteosarcoma cells after treatment with doxorubicin in the presence of extracellular matrix biopolymers.
Harisi R; Dudás J; Pogány G; Timár F; Oláh JN; Szendroi M; Jeney A
Cancer Chemother Pharmacol; 2006 Sep; 58(3):334-42. PubMed ID: 16534616
[TBL] [Abstract][Full Text] [Related]
4. P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.
Long X; Lin XJ
J Cell Biochem; 2019 Apr; 120(4):5652-5665. PubMed ID: 30387173
[TBL] [Abstract][Full Text] [Related]
5. Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.
Spina A; Sorvillo L; Di Maiolo F; Esposito A; D'Auria R; Di Gesto D; Chiosi E; Naviglio S
J Cell Physiol; 2013 Jan; 228(1):198-206. PubMed ID: 22674530
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
7. Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture.
Harisi R; Dudás J; Timár F; Pogány G; Timár J; Kovalszky I; Szendroi M; Jeney A
Cell Biol Int; 2005 Nov; 29(11):959-67. PubMed ID: 16242975
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?
Hattinger CM; Fanelli M; Tavanti E; Vella S; Riganti C; Picci P; Serra M
Future Oncol; 2017 Apr; 13(8):673-677. PubMed ID: 28183198
[No Abstract] [Full Text] [Related]
9. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Estrogen Receptor Alpha Inhibits Cell Proliferation, Differentiation and Enhances the Chemosensitivity of P53-Positive U2OS Osteosarcoma Cell.
Wang JY; Chen CM; Chen CF; Wu PK; Chen WM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681897
[TBL] [Abstract][Full Text] [Related]
11. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins.
Gonçalves C; Martins-Neves SR; Paiva-Oliveira D; Oliveira VE; Fontes-Ribeiro C; Gomes CM
Life Sci; 2015 Jun; 130():47-56. PubMed ID: 25818183
[TBL] [Abstract][Full Text] [Related]
13. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.
Kusuzaki K; Takeshita H; Murata H; Hirata M; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer; 1998 Jun; 82(12):2343-9. PubMed ID: 9635526
[TBL] [Abstract][Full Text] [Related]
14. [Sensitivity of doxorubicin-resistant osteosarcoma cells to doxorubicin regulated by long non-coding RNA NR_036444].
Zhu KP; Zhang CL
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):250-255. PubMed ID: 28550663
[No Abstract] [Full Text] [Related]
15. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
Hu T; Fei Z; Su H; Xie R; Chen L
Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis.
Zhou B; Li L; Li Y; Sun H; Zeng C
Biomed Pharmacother; 2018 Oct; 106():850-857. PubMed ID: 30119255
[TBL] [Abstract][Full Text] [Related]
18. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
20. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
